Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
This study proposes to transfer marker genes (detectable genetic traits or segments of DNA
that can be identified and tracked) into aliquots of marrow obtained for Bone Marrow
Transplant (BTM) in patients in remission of Acute Myelogenous Leukemia (AML).